A study budget is the structured financial planning of a specific clinical trial. It allocates costs to the planned services, quantities, time points, and responsibilities and serves for control during the conduct. The study budget comprises the costs of the trial itself; it is not to be equated with the total development or marketing costs of a medicinal product or medical device.
Cost blocks and site compensation
A robust study budget breaks down costs according to work packages, units, and assumptions. Typical blocks are feasibility and start-up, regulatory and ethical documents, contracts, project management, site management, and monitoring. In addition, there are expenses for data management, biostatistics, medical writing, pharmacovigilance, quality assurance, investigational medicinal products, depot and transport logistics, laboratory, imaging, translations, insurances, and technical systems. Which blocks are required depends on the protocol, countries, sites, intervention, and data collection.
The planning should clearly indicate whether an item is incurred on a one-off basis, per site, per participant, per visit, or time-dependently. Especially with complex protocols, a traceable allocation to assessments and visits is important. It makes it possible to translate changes to the protocol or recruitment assumptions into their cost consequences. Regulation (EU) No 536/2014 requires information on financial and other arrangements for the application context; at the same time, national requirements regarding compensation and insurance must be observed.
Site compensation comprises the contractually agreed reimbursement or remuneration of the study-specific services provided at the study site. This can include start-up activities, visits, assessments, documentation, storage of investigational medicinal products, archiving, or the handling of queries. The budget should unambiguously describe services, billing rules, payment dates, and any necessary evidence. The agreement must fit the actual workload and be transparently separated from other funding streams.
Reimbursements or payments to participants as well as the coverage of study-related damages are to be distinguished from site compensation. Documents for the clinical trial must contain information on corresponding arrangements, insofar as this is required by applicable law. Compensations must not inappropriately influence the voluntary decision. A study budget maps such items, but does not solely decide on their ethical acceptability; the ethics committee and applicable national requirements remain decisive.
Pass-through costs, change orders and control
Pass-through costs are expenses of external providers that are treated separately in the project contract, which are incurred for the study and usually passed on without being part of the regular service fee. Examples can be central laboratories, courier services, imaging providers, translations, participant travel, or fees. The exact definition, requirement for receipts, and treatment of mark-ups result from the contract. Pass-through is therefore not a regulatory category, but a commercial agreement that should be unambiguously regulated in the budget.
A change order documents an agreed change to the scope, assumptions, timeline, or costs. Triggers can be protocol amendments, additional countries or sites, changed participant numbers, extended durations, or new safety requirements. Prior to the conduct of the additional services, it should describe what changes and what budget and time consequences arise. A change order does not replace a required regulatory approval of a substantial modification.
A budget remains a working instrument during the conduct. Planned and actual costs, outstanding obligations, and the forecast until the end of the study should be compared regularly. Documented assumptions are essential, for example regarding recruitment rate, number of activated sites, visit volume, and required monitoring intensity. Deviations do not necessarily have to be an error, but should be recognized, explained, and, if necessary, made traceable by an approved budget modification.
Financial control must not compromise quality or safety. If additional measures become necessary due to safety data, a regulatory requirement, or a changed protocol, their necessity and their financing must be cleanly mapped. Conversely, a supposedly inexpensive approach that does not account for realistic resources at the site or data quality can lead to later delays and additional costs. Risk-based planning therefore combines scientific, operational, and financial assumptions.
Differentiation from total development costs
The study budget relates to a defined clinical trial with its protocol, countries, sites, and durations. Total development costs, in contrast, capture the broader life cycle of a product. This can include preclinical research, pharmaceutical development and manufacturing, multiple clinical programs, regulatory affairs activities, market preparation, and later obligations. A study budget is thus a part of overall financial planning, but not a complete product calculation.
A program with multiple studies also regularly requires separate budgets, because objectives, populations, risks, and operational models differ. The sum of individual study budgets is not readily equated with total development costs. Shared infrastructure or overarching activities must be transparently allocated. This differentiation creates clarity for responsibilities, contract management, and the evaluation of changes.
Relevance for clinical trials
A traceable study budget ensures that sufficient resources are planned for conduct in accordance with the protocol. It makes cost assumptions, site compensation, external services, and consequences of changes visible. In everyday study practice, it supports the connection between project progress and financial control, without replacing the medical and ethical evaluation of decisions by purely commercial criteria.
Full-service CROs such as Mediconomics support with cost models, scopes of work, site budgets, contract processes, and the forecasting of effort and expenses. They coordinate project management, clinical operations, monitoring, data management, pharmacovigilance, and regulatory affairs so that budget assumptions remain consistent with protocol, timeline, documentation, and required change processes.
Frequently Asked Questions (FAQ)
What typically belongs in a study budget?
Typical items are start-up, site compensation, monitoring, data management, safety monitoring, investigational medicinal product and logistics, laboratory services, insurances, technical systems, and external services. The specific scope depends on the protocol.
Are pass-through costs automatically without mark-up?
No. Pass-through describes a contractual treatment of external expenses. Whether mark-ups, caps, receipts, or payment routes apply must be unambiguously defined in the respective contract and budget.
Is a change order an approval for a protocol amendment?
No. A change order regulates the scope of services, time, and costs in the contractual relationship. Required regulatory submissions and approvals for a substantial modification remain separate from this.
Regulatory references
- Regulation (EU) No 536/2014 on clinical trials — financial arrangements, insurance, and protection of participants.
- ICH E6(R3) Good Clinical Practice — adequate resources, quality management, and protection of participants.
- ICH E8(R1) General Considerations for Clinical Studies — quality-by-design and risk-based study planning.
- EudraLex Volume 10 — documents on financial and other arrangements in the CTIS procedure.